Most Researched Recovery Peptides: What the Literature Shows

BPC-157 is arguably the most studied recovery peptide, with >100 publications in animal models. It derives from a fragment of the gastric protein BPC. Mechanisms: angiogenesis (VEGF), nitric oxide, FAK-paxillin pathway, GH receptor regulation. Studied in tendons, muscles, gastrointestinal ulcers, nerve regeneration. Minimal published human data.

Thymosin β4 is a 43-amino-acid protein that regulates actin polymerization. TB-500 is a synthetic fragment. Mechanisms: cell migration, anti-inflammatory action, angiogenesis, fibrosis reduction. Studied in skin wounds, cardiac repair, corneal healing. RGN-259 (topical thymosin β4) progressed to ophthalmology clinical trials.

GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) bound to copper. Mechanisms: collagen synthesis stimulation, tissue remodeling, antioxidant action, regulation of healing-related genes (>4,000 genes reported). Studied topically for skin/hair and systemically for tissue repair.

KPV (Lys-Pro-Val) derives from the C-terminal segment of α-MSH. Mechanisms: NF-κB inhibition, TNF-α and IL-6 reduction, antimicrobial action. Studied primarily in inflammatory bowel disease (IBD) models and skin inflammation. Data is primarily preclinical.

LL-37 is a 37-amino-acid antimicrobial peptide that is part of the innate immune system. Mechanisms: antimicrobial action, inflammation regulation, angiogenesis, cell migration stimulation. Studied for infected wounds, chronic wounds, and tissue repair.

BPC-157: Largest volume of preclinical studies (100+), minimal human data. TB-500/Thymosin β4: Strong in vitro data, clinical trials primarily in ophthalmology. GHK-Cu: Topical application well-documented, less data for systemic use. KPV: Newer findings, primarily in vitro/animal. LL-37: Natural peptide with strong basic research.